About Iovance Biotherapeutics Inc. Iovance Biotherapeutics Inc. is the global leader in innovating developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved one-time treatment for previously treated advanced melanoma now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors including gene-edited and IL-12 tethered TIL therapies next-generation IL-2 and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment Iovance operates as an end-to-end cell therapy company anchored by fully owned centralized U.S.-based manufacturing that is scaled to serve … Sign In to View